Genuine Tarceva taking agent purchase and sale Tarceva price 13621079267

'r ', ' ', [Drug name] Tarceva (erlotinib hydrochloride)<
'r ', ' ', #[Specification]
'r ', ' ', #[ Storage] Store at ℃, temperatures between ℃ and ℃ are also acceptable.
'r ', ' ', #[Packaging] Blister packaging sheet/box.
'r ', ' ', #【New package】tablets/bottle
'r ', ' ', #【Validity period】months
'r ', ' ', #【Production Enterprise] Indian Pharmaceutical
'r ', ' ', #[Ingredients] Each tablet contains erlotinib (in the form of erlotinib hydrochloride)
'r ', ' ', #[ Appearance] Round, biconvex, white coated tablets.
'r ', ' ', #[Mechanism of action] The anti-tumor mechanism of r is mainly to inhibit the intracellular phosphorylation of epidermal growth factor (R) tyrosine kinase.
'r ', ' ', #[Pharmacokinetics]
'r ', ' ', #r% absorbed after oral administration, half-life is about hours, and is mainly eliminated by metabolism. The bioavailability of r after oral administration is approximately %, and peak plasma concentration is reached after several hours. Pharmacokinetic analysis of the patient treated with a single drug r showed that it takes - days to reach stable blood concentration. The patient's age, weight, and gender have no significant relationship with the drug clearance rate. Smoking can increase the drug clearance rate by %.
'r ', ' ', #[Indications]
'r ', ' ', #rFor locally advanced or metastatic non-small cell lung cancer that has failed two or more chemotherapy regimens third-line treatment.
'r ', ' ', #【Contraindications】
'r ', ' ', #Contraindicated for those who are allergic to this product and its ingredients.
'r ', ' ', #[Adverse reactions]
'r ', ' ', #The most common adverse reactions are rash and diarrhea, and the incidence rates of rash and diarrhea are % and % respectively %, the median onset of rash was days, and the median onset of diarrhea was days.
'r ', ' ', #Adverse reactions with an incidence rate greater than % include: rash, diarrhea, decreased appetite, fatigue, dyspnea, cough, nausea, infection, vomiting, stomatitis, itching, dry skin, conjunctiva inflammation, keratoconjunctivitis, abdominal pain.
'r ', ' ', #【Pulmonary Toxicity】
'r ', ' ', #There are few reports suggesting that serious toxicity may occur in patients treated with r or in patients with other solid tumors. Interstitial lung disease (interstitial lung disease), even leading to death. In randomized controlled studies, the incidence rate was .% and was the same in the r treatment and placebo groups. Reported include: pneumonia, interstitial pneumonia, interstitial lung disease, bronchiolitis obliterans, pulmonary fibrosis, acute respiratory stress syndrome, and pulmonary effusion. Symptoms occurred from the day after treatment to more than one month, with a median onset time of days. Most patients often have confounding factors, such as previous chemotherapy/radiation therapy, existing parenchymal lung disease, lung metastasis or lung infection. When there are new and unexplained pulmonary symptoms, such as dyspnea, cough, fever, etc., examination and evaluation are required. Once diagnosed, use of r should be stopped and appropriate treatment should be taken.